|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Phamacological Institute (Y.-N.L., S.-L.P., C.-Y.P., D.-M.H., Y.-L.C., C.-H.L., H.-C.P., C.-M.T.), College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy (J.-H.G.), College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Pharmaceutical Chemistry (S.-C.K.), China Medical University, Taichung, Taiwan; and Yung-Shin Pharmaceutical Industry Co., Ltd. (F.-Y.L.), Taichung, Taiwan
Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, and postrevascularization production of vascular smooth muscle cells may play key roles in development of arterial restenosis. We investigated the inhibitory effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a benzyl indazole compound, on MMP-2 and MMP-9 activity in a balloon-injury rat carotid artery model. Injury was induced by inserting a balloon catheter through the common carotid artery; after 14 days, histopathological analysis using immunostaining and Western blotting revealed significant restenosis with neointimal formation that was associated with enhanced protein expression of MMP-2 and MMP-9. However, these effects were dose-dependently reduced by orally administered YC-1 (110 mg/kg). In addition, gelatin zymography demonstrated that increased MMP-2 and MMP-9 activity was diminished by YC-1 treatment. On the other hand, YC-1 inhibited hydrolysis of the fluorogenic quenching substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by recombinant MMP-2 and MMP-9 with IC50 values = 2.07 and 8.20 µM, respectively. Reverse transcription-polymerase chain reaction analysis of MMP-2 and MMP-9 mRNA revealed that YC-1 significantly inhibited mRNA levels of MMPs. Finally, for the YC-1 treatment group, we did not observe elevation of cGMP levels using enzyme-linked immunosorbent assay, suggesting that YC-1 inhibition of neointimal formation is not through a cGMP-elevating pathway. These data show YC-1 suppression of neointimal formation is dependent on its influence on MMP-2 and MMP-9 protein, mRNA expression, and activity, but not through a cGMP-elevating effect. YC-1 shows therapeutic potential for treatment of restenosis after angioplasty.
Address correspondence to: Dr. Che-Ming Teng, Pharmacological Institute, College of Medicine, National Taiwan University, 1, Jen-Ai Road, Sect. 1, Taipei, Taiwan. E-mail: cmteng{at}ha.mc.ntu.edu.tw
This article has been cited by other articles:
![]() |
K. Hirschberg, T. Radovits, S. Loganathan, L. Entz, C. J. Beller, M.-L. Gross, P. Sandner, M. Karck, and G. Szabo Selective phosphodiesterase-5 inhibition reduces neointimal hyperplasia in rat carotid arteries after surgical endarterectomy. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1508 - 1514. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Keswani, K. J. Peyton, W. Durante, A. I. Schafer, and D. A. Tulis The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 116 - 124. [Abstract] [PDF] |
||||
![]() |
X.-m. Liu, K. J. Peyton, N. N. Mendelev, H. Wang, D. A. Tulis, and W. Durante YC-1 Stimulates the Expression of Gaseous Monoxide-Generating Enzymes in Vascular Smooth Muscle Cells Mol. Pharmacol., January 1, 2009; 75(1): 208 - 217. [Abstract] [Full Text] [PDF] |
||||